CIBC World Markets Inc. purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 10,712 shares of the life sciences company’s stock, valued at approximately $2,340,000.

Several other large investors also recently made changes to their positions in the company. Jennison Associates LLC increased its holdings in shares of Illumina by 8.8% in the 4th quarter. Jennison Associates LLC now owns 4,412,621 shares of the life sciences company’s stock valued at $964,114,000 after acquiring an additional 355,200 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Illumina by 3.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock valued at $500,416,000 after acquiring an additional 76,452 shares during the period. Legal & General Group Plc increased its holdings in shares of Illumina by 2.6% in the 3rd quarter. Legal & General Group Plc now owns 684,955 shares of the life sciences company’s stock valued at $136,442,000 after acquiring an additional 17,081 shares during the period. American Century Companies Inc. increased its holdings in shares of Illumina by 27.4% in the 3rd quarter. American Century Companies Inc. now owns 605,149 shares of the life sciences company’s stock valued at $120,546,000 after acquiring an additional 130,038 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its holdings in shares of Illumina by 6.4% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 541,063 shares of the life sciences company’s stock valued at $118,217,000 after acquiring an additional 32,695 shares during the period. Institutional investors and hedge funds own 91.71% of the company’s stock.

ILMN has been the subject of a number of recent analyst reports. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $252.00 price objective for the company in a research report on Tuesday, December 5th. Deutsche Bank raised Illumina from a “hold” rating to a “buy” rating and lowered their price objective for the stock from $195.00 to $160.00 in a research report on Monday, October 23rd. Canaccord Genuity reissued a “buy” rating and issued a $230.00 price objective (up previously from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Bank of America raised their price objective on Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Finally, BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $240.61.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $210.59, for a total transaction of $4,211,800.00. Following the completion of the transaction, the director now owns 536,717 shares in the company, valued at approximately $113,027,233.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Oene Mark Van sold 1,250 shares of Illumina stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $207.76, for a total value of $259,700.00. Following the transaction, the senior vice president now owns 11,691 shares of the company’s stock, valued at approximately $2,428,922.16. The disclosure for this sale can be found here. Insiders have sold a total of 132,312 shares of company stock valued at $28,974,614 in the last quarter. Company insiders own 0.89% of the company’s stock.

Illumina, Inc. (ILMN) opened at $220.18 on Friday. The firm has a market capitalization of $30,740.00, a PE ratio of 44.66, a price-to-earnings-growth ratio of 3.04 and a beta of 0.92. Illumina, Inc. has a 52 week low of $158.02 and a 52 week high of $248.97. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.73 and a current ratio of 3.99.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.22. The business had revenue of $778.00 million during the quarter, compared to analyst estimates of $752.04 million. Illumina had a return on equity of 21.52% and a net margin of 26.56%. The company’s revenue was up 25.7% on a year-over-year basis. During the same quarter last year, the business posted $0.85 EPS. equities research analysts expect that Illumina, Inc. will post 4.59 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://theolympiareport.com/2018/02/04/cibc-world-markets-inc-purchases-new-holdings-in-illumina-inc-ilmn.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.